Limits...
The Effect of Comorbidity on Glycemic Control and Systolic Blood Pressure in Type 2 Diabetes: A Cohort Study with 5 Year Follow-Up in Primary Care.

Luijks H, Biermans M, Bor H, van Weel C, Lagro-Janssen T, de Grauw W, Schermer T - PLoS ONE (2015)

Bottom Line: In subgroup effect analyses we tested if potential differences were modified by age, sex, socioeconomic status, and BMI.Patients with cardiovascular diseases had sustained elevated levels of SBP (p = 0.014).Effect modification by socioeconomic status was observed in some comorbidity subgroups.

View Article: PubMed Central - PubMed

Affiliation: Department of Primary and Community Care, Radboud university medical center, Nijmegen, The Netherlands.

ABSTRACT

Aims: To explore the longitudinal effect of chronic comorbid diseases on glycemic control (HbA1C) and systolic blood pressure (SBP) in type 2 diabetes patients.

Methods: In a representative primary care cohort of patients with newly diagnosed type 2 diabetes in The Netherlands (n = 610), we tested differences in the five year trend of HbA1C and SBP according to comorbidity profiles. In a mixed model analysis technique we corrected for relevant covariates. Influence of comorbidity (a chronic disease already present when diabetes was diagnosed) was tested as total number of comorbid diseases, and as presence of specific disease groups, i.e. cardiovascular, mental, and musculoskeletal disease, malignancies, and COPD. In subgroup effect analyses we tested if potential differences were modified by age, sex, socioeconomic status, and BMI.

Results: The number of comorbid diseases significantly influenced the SBP trend, with highest values after five years for diabetes patients without comorbidity (p = 0.005). The number of diseases did not influence the HbA1C trend (p = 0.075). Comorbid musculoskeletal disease resulted in lower HbA1C at the time of diabetes diagnosis, but in higher values after five years (p = 0.044). Patients with cardiovascular diseases had sustained elevated levels of SBP (p = 0.014). Effect modification by socioeconomic status was observed in some comorbidity subgroups.

Conclusions: Presence of comorbidity in type 2 diabetes patients affected the long-term course of HbA1C and SBP in this primary care cohort. Numbers and types of comorbidity showed differential effects: not the simple sum of diseases, but specific types of comorbid disease had a negative influence on long-term diabetes control parameters. The complex interactions between comorbidity, diabetes control and effect modifiers require further investigation and may help to personalize treatment goals.

No MeSH data available.


Related in: MedlinePlus

Flow chart of patient selection from the CMR general practice database.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4591264&req=5

pone.0138662.g001: Flow chart of patient selection from the CMR general practice database.

Mentions: We identified 714 patients with a new diagnosis of type 2 diabetes within the study period (1985–2006). Outcome measurements were available in 684 patients. Of these, 610 patients had a first measurement of HbA1C and/or SBP within four months from diagnosis and were included for longitudinal analysis. Fig 1 shows a flow chart of our study population.


The Effect of Comorbidity on Glycemic Control and Systolic Blood Pressure in Type 2 Diabetes: A Cohort Study with 5 Year Follow-Up in Primary Care.

Luijks H, Biermans M, Bor H, van Weel C, Lagro-Janssen T, de Grauw W, Schermer T - PLoS ONE (2015)

Flow chart of patient selection from the CMR general practice database.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4591264&req=5

pone.0138662.g001: Flow chart of patient selection from the CMR general practice database.
Mentions: We identified 714 patients with a new diagnosis of type 2 diabetes within the study period (1985–2006). Outcome measurements were available in 684 patients. Of these, 610 patients had a first measurement of HbA1C and/or SBP within four months from diagnosis and were included for longitudinal analysis. Fig 1 shows a flow chart of our study population.

Bottom Line: In subgroup effect analyses we tested if potential differences were modified by age, sex, socioeconomic status, and BMI.Patients with cardiovascular diseases had sustained elevated levels of SBP (p = 0.014).Effect modification by socioeconomic status was observed in some comorbidity subgroups.

View Article: PubMed Central - PubMed

Affiliation: Department of Primary and Community Care, Radboud university medical center, Nijmegen, The Netherlands.

ABSTRACT

Aims: To explore the longitudinal effect of chronic comorbid diseases on glycemic control (HbA1C) and systolic blood pressure (SBP) in type 2 diabetes patients.

Methods: In a representative primary care cohort of patients with newly diagnosed type 2 diabetes in The Netherlands (n = 610), we tested differences in the five year trend of HbA1C and SBP according to comorbidity profiles. In a mixed model analysis technique we corrected for relevant covariates. Influence of comorbidity (a chronic disease already present when diabetes was diagnosed) was tested as total number of comorbid diseases, and as presence of specific disease groups, i.e. cardiovascular, mental, and musculoskeletal disease, malignancies, and COPD. In subgroup effect analyses we tested if potential differences were modified by age, sex, socioeconomic status, and BMI.

Results: The number of comorbid diseases significantly influenced the SBP trend, with highest values after five years for diabetes patients without comorbidity (p = 0.005). The number of diseases did not influence the HbA1C trend (p = 0.075). Comorbid musculoskeletal disease resulted in lower HbA1C at the time of diabetes diagnosis, but in higher values after five years (p = 0.044). Patients with cardiovascular diseases had sustained elevated levels of SBP (p = 0.014). Effect modification by socioeconomic status was observed in some comorbidity subgroups.

Conclusions: Presence of comorbidity in type 2 diabetes patients affected the long-term course of HbA1C and SBP in this primary care cohort. Numbers and types of comorbidity showed differential effects: not the simple sum of diseases, but specific types of comorbid disease had a negative influence on long-term diabetes control parameters. The complex interactions between comorbidity, diabetes control and effect modifiers require further investigation and may help to personalize treatment goals.

No MeSH data available.


Related in: MedlinePlus